- Home
- ENVB vs AKAN Comparison
ENVB vs AKAN Comparison
Compare ENVB & AKAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- AKAN
- Stock Information
- Founded
- ENVB 1994
- AKAN 2021
- Country
- ENVB United States
- AKAN Canada
- Employees
- ENVB N/A
- AKAN N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- AKAN Medicinal Chemicals and Botanical Products
- Sector
- ENVB Health Care
- AKAN Health Care
- Exchange
- ENVB Nasdaq
- AKAN Nasdaq
- Market Cap
- ENVB 3.0M
- AKAN 2.9M
- IPO Year
- ENVB N/A
- AKAN 2022
- Fundamental
- Price
- ENVB $0.97
- AKAN $3.58
- Analyst Decision
- ENVB Strong Buy
- AKAN
- Analyst Count
- ENVB 1
- AKAN 0
- Target Price
- ENVB $10.00
- AKAN N/A
- AVG Volume (30 Days)
- ENVB 325.7K
- AKAN 158.9K
- Earning Date
- ENVB 08-14-2025
- AKAN 10-29-2025
- Dividend Yield
- ENVB N/A
- AKAN N/A
- EPS Growth
- ENVB N/A
- AKAN N/A
- EPS
- ENVB N/A
- AKAN N/A
- Revenue
- ENVB N/A
- AKAN $836,664.00
- Revenue This Year
- ENVB N/A
- AKAN N/A
- Revenue Next Year
- ENVB N/A
- AKAN N/A
- P/E Ratio
- ENVB N/A
- AKAN N/A
- Revenue Growth
- ENVB N/A
- AKAN 97.47
- 52 Week Low
- ENVB $0.85
- AKAN $2.91
- 52 Week High
- ENVB $8.33
- AKAN $8.75
- Technical
- Relative Strength Index (RSI)
- ENVB 40.51
- AKAN 46.62
- Support Level
- ENVB $0.85
- AKAN $3.14
- Resistance Level
- ENVB $1.06
- AKAN $3.86
- Average True Range (ATR)
- ENVB 0.10
- AKAN 0.40
- MACD
- ENVB -0.02
- AKAN -0.04
- Stochastic Oscillator
- ENVB 19.34
- AKAN 35.20
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.